Rebecca Langhough Koscik
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Rebecca Langhough Koscik has a total of 186 co-authors. Here are the top co-authors by number of shared publications:
- Sterling C. Johnson
Wisconsin Alzheimer’s Disease Research Center, School of Medicine and Public Health, University of Wisconsin, Madison, USA
19 shared publications Bruce P. Hermann
Wisconsin Alzheimer's Institute University of Wisconsin‐Madison School of Medicine and Public Health Madison Wisconsin USA
13 shared publicationsErin M. Jonaitis
Wisconsin Alzheimer's Institute University of Wisconsin‐Madison School of Medicine and Public Health Madison Wisconsin USA
11 shared publicationsSterling C. Johnson
Wisconsin Alzheimer's Institute University of Wisconsin‐Madison School of Medicine and Public Health Madison Wisconsin USA
10 shared publicationsKimberly D. Mueller
Department of Communication Sciences and Disorders University of Wisconsin – Madison Madison Wisconsin USA
9 shared publicationsLindsay R. Clark
Division of Geriatrics University of Wisconsin – Madison Madison Wisconsin USA
9 shared publications
Latest Publications
- 11 September 2025
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 107 (4) , 1481-1497
Linking silent pause locations in speech to amyloid and tau deposition in cognitively unimpaired individuals
Background: Connected speech and language (CSL) analysis can differentiate typically aging individuals from those with dementia by identifying subtle changes in language-dependent measures, such as lexical diversity and fluency. Prior studies have linked features like slower speech rates and increased silent pauses with Alzheimer's disease (AD) neuropathology, but the pause patterns in preclinical AD and their syntactic locations remain unclear. Objective: To investigate silent pauses as a potential early detection tool for AD in cognitively unimpaired individuals and compare their sensitivity to traditional neuropsychological tests in distinguishing biomarker-positive and biomarker-negative groups. Methods: Cognitively unimpaired participants from the Wisconsin Registry for Alzheimer's Prevention with amyloid (A) and tau (T) PET imaging were included. Twenty-six participants with A+/T+ profiles were matched 1:1 with A-/T- individuals using propensity score matching for age, sex, literacy, and race (n = 52). Participants were majority female (75.6%) and non-Hispanic white (91%) with a mean (sd) age of 67.5 (6.2). CSL samples were derived from the Cookie Theft picture description task closest to PET scans. Pauses were annotated using ELAN at utterance-initial, clause-initial, and within-clause locations, with further categorization of within-clause pauses by part of speech (nouns, verbs, adjectives/adverbs). Pause rates and durations were analyzed using Mann-Whitney U tests, with effect sizes measured by Cliff's delta (δ). Results: A+/T+ individuals had longer adjective/adverb-initial pauses than A-/T- ( p = 0.016; δ = 0.39), outperforming the preclinical Alzheimer's cognitive composite ( p = 0.347, δ = 0.15). Conclusions: Silent pauses, especially adjective/adverb-initial, show promise as an early indicator of AD neuropathology. Replication in diverse cohorts with longitudinal analyses is warranted.
- 11 September 2025
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 107 (4) , 1481-1497
Linking silent pause locations in speech to amyloid and tau deposition in cognitively unimpaired individuals
Background: Connected speech and language (CSL) analysis can differentiate typically aging individuals from those with dementia by identifying subtle changes in language-dependent measures, such as lexical diversity and fluency. Prior studies have linked features like slower speech rates and increased silent pauses with Alzheimer's disease (AD) neuropathology, but the pause patterns in preclinical AD and their syntactic locations remain unclear. Objective: To investigate silent pauses as a potential early detection tool for AD in cognitively unimpaired individuals and compare their sensitivity to traditional neuropsychological tests in distinguishing biomarker-positive and biomarker-negative groups. Methods: Cognitively unimpaired participants from the Wisconsin Registry for Alzheimer's Prevention with amyloid (A) and tau (T) PET imaging were included. Twenty-six participants with A+/T+ profiles were matched 1:1 with A-/T- individuals using propensity score matching for age, sex, literacy, and race (n = 52). Participants were majority female (75.6%) and non-Hispanic white (91%) with a mean (sd) age of 67.5 (6.2). CSL samples were derived from the Cookie Theft picture description task closest to PET scans. Pauses were annotated using ELAN at utterance-initial, clause-initial, and within-clause locations, with further categorization of within-clause pauses by part of speech (nouns, verbs, adjectives/adverbs). Pause rates and durations were analyzed using Mann-Whitney U tests, with effect sizes measured by Cliff's delta (δ). Results: A+/T+ individuals had longer adjective/adverb-initial pauses than A-/T- ( p = 0.016; δ = 0.39), outperforming the preclinical Alzheimer's cognitive composite ( p = 0.347, δ = 0.15). Conclusions: Silent pauses, especially adjective/adverb-initial, show promise as an early indicator of AD neuropathology. Replication in diverse cohorts with longitudinal analyses is warranted.
- Open Access
- 1 July 2025
- Published by Wiley in Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring
- Vol. 17 (3)
Preclinical dementia rating scores are associated with plasma phosphorylated tau‐217
INTRODUCTION: Simple screening tools are critical for assessing Alzheimer's disease (AD)‐related pre‐dementia changes. This study investigated longitudinal scores from the Quick Dementia Rating System (QDRS), a brief study partner‐reported measure, in relation to baseline levels of the AD biomarker plasma pTau217 in individuals unimpaired at baseline.METHODS: Data from the Wisconsin Registry for Alzheimer's Prevention (N = 639) were used to examine whether baseline plasma pTau217 (ALZpath assay on Quanterix platform) modified QDRS or Preclinical Alzheimer's Cognitive Composite (PACC3) trajectories (mixed‐effects models; time = age). pTau217*age interaction effects (e.g., high vs low pTau217 simple age slopes) were compared across outcomes.RESULTS: Higher baseline pTau217 levels were associated with faster functional (QDRS) and cognitive (PACC3) decline. Effect sizes were similar between PACC3 and QDRS. Exploratory analyses showed increased risk of transitioning to impaired QDRS classifications in those with high‐baseline pTau217.DISCUSSION: This study demonstrates the utility of QDRS for tracking pre‐dementia AD‐related decline.
- 1 July 2025
- Published by Wiley in Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring
- Vol. 17 (3)
Open AccessPreclinical dementia rating scores are associated with plasma phosphorylated tau‐217
INTRODUCTION: Simple screening tools are critical for assessing Alzheimer's disease (AD)‐related pre‐dementia changes. This study investigated longitudinal scores from the Quick Dementia Rating System (QDRS), a brief study partner‐reported measure, in relation to baseline levels of the AD biomarker plasma pTau217 in individuals unimpaired at baseline.METHODS: Data from the Wisconsin Registry for Alzheimer's Prevention (N = 639) were used to examine whether baseline plasma pTau217 (ALZpath assay on Quanterix platform) modified QDRS or Preclinical Alzheimer's Cognitive Composite (PACC3) trajectories (mixed‐effects models; time = age). pTau217*age interaction effects (e.g., high vs low pTau217 simple age slopes) were compared across outcomes.RESULTS: Higher baseline pTau217 levels were associated with faster functional (QDRS) and cognitive (PACC3) decline. Effect sizes were similar between PACC3 and QDRS. Exploratory analyses showed increased risk of transitioning to impaired QDRS classifications in those with high‐baseline pTau217.DISCUSSION: This study demonstrates the utility of QDRS for tracking pre‐dementia AD‐related decline.
- Open Access
Use of preclinical Alzheimer’s disease trajectories for clinical trial design
INTRODUCTION This study uses longitudinal amyloid biomarker and cognitive data to generate sample size estimates for two-armed, pre-clinical amyloid clearance clinical trials. METHODS PET PiB DVR ranges defined three amyloid groups (positive, “A+”; sub threshold/low positive, “subA+”; and negative, “A-”) in cognitively unimpaired Wisconsin Registry for Alzheimer’s Prevention participants. Amyloid group trajectories estimated from mixed effects models informed per-treatment-arm sample size estimates to detect plausible treatment effects over 3-year (biomarker) or 6-year (cognition) study windows (80% power). RESULTS To detect ≥60% slowing in PiB accumulation, ≤40 may be needed per arm for both SubA+ and A+; to detect the same effect sizes in plasma p-tau217 trajectories, ∼50-1700 are needed, depending on assay and amyloid subgroup. Among cognitive outcomes, Digit Symbol Substitution and a 5-test Preclinical Alzheimer’s Cognitive Composite consistently required fewest (DISCUSSION Early intervention study planning will benefit from selection of outcomes that are most sensitive to AD biomarker-related preclinical change.
Open AccessUse of preclinical Alzheimer’s disease trajectories for clinical trial design
INTRODUCTION This study uses longitudinal amyloid biomarker and cognitive data to generate sample size estimates for two-armed, pre-clinical amyloid clearance clinical trials. METHODS PET PiB DVR ranges defined three amyloid groups (positive, “A+”; sub threshold/low positive, “subA+”; and negative, “A-”) in cognitively unimpaired Wisconsin Registry for Alzheimer’s Prevention participants. Amyloid group trajectories estimated from mixed effects models informed per-treatment-arm sample size estimates to detect plausible treatment effects over 3-year (biomarker) or 6-year (cognition) study windows (80% power). RESULTS To detect ≥60% slowing in PiB accumulation, ≤40 may be needed per arm for both SubA+ and A+; to detect the same effect sizes in plasma p-tau217 trajectories, ∼50-1700 are needed, depending on assay and amyloid subgroup. Among cognitive outcomes, Digit Symbol Substitution and a 5-test Preclinical Alzheimer’s Cognitive Composite consistently required fewest (DISCUSSION Early intervention study planning will benefit from selection of outcomes that are most sensitive to AD biomarker-related preclinical change.
- Open Access
Factors associated with age at tau pathology onset and time from tau onset to dementia
INTRODUCTION: Elevated tau is temporally proximal to dementia onset but less is known about factors influencing T+ onset age and time to dementia following T+ in Alzheimer’s disease. We used sampled iterative localized approximation (SILA) estimated T+ onset age (ETOA) to investigate factors associated with T+ age and time from T+ to dementia onset in ADNI. METHODS: Using SILA-estimated A+ and T+ onset ages derived from 18 F-Flortaucipir, 18 F-Florbetapir, and 18 F-Florbetaben PET and Cox proportional hazards and accelerated failure time models, we analyzed APOE , sex, amyloid burden, age, educational attainment, and literacy associations with ETOA and time from T+ to dementia. RESULTS: Higher amyloid, APOE -ε4, lower education, and lower literacy associated with younger ETOA. Older ETOA and higher amyloid associated with shorter time from T+ to dementia. DISCUSSION: This work highlights the prognostic value of ETOA and the need to better characterize factors contributing to ETOA and dementia onset in AD.
Open AccessFactors associated with age at tau pathology onset and time from tau onset to dementia
INTRODUCTION: Elevated tau is temporally proximal to dementia onset but less is known about factors influencing T+ onset age and time to dementia following T+ in Alzheimer’s disease. We used sampled iterative localized approximation (SILA) estimated T+ onset age (ETOA) to investigate factors associated with T+ age and time from T+ to dementia onset in ADNI. METHODS: Using SILA-estimated A+ and T+ onset ages derived from 18 F-Flortaucipir, 18 F-Florbetapir, and 18 F-Florbetaben PET and Cox proportional hazards and accelerated failure time models, we analyzed APOE , sex, amyloid burden, age, educational attainment, and literacy associations with ETOA and time from T+ to dementia. RESULTS: Higher amyloid, APOE -ε4, lower education, and lower literacy associated with younger ETOA. Older ETOA and higher amyloid associated with shorter time from T+ to dementia. DISCUSSION: This work highlights the prognostic value of ETOA and the need to better characterize factors contributing to ETOA and dementia onset in AD.
- Open Access
- 23 December 2024
- Published by Wiley in Alzheimer's & Dementia
- Vol. 21 (2)
Performance of study partner reports in a non‐demented at‐risk sample
INTRODUCTION: The Clinical Dementia Rating (CDR) Scale is a gold standard for staging impairment in Alzheimer's disease and other dementias (ADRD). The Quick Dementia Rating System (QDRS) offers similar results in 3 to 5 minutes without a trained clinician. This study aimed to (1) investigate concordance between comparably derived QDRS and CDR global scores, (2) examine item‐level QDRS/CDR agreement, and (3) compare sample characteristics and cognitive performance across QDRS/CDR global concordant/discordant groups. METHODS: The study included 351 QDRS/CDR pairs from 297 participants in the Wisconsin Registry for Alzheimer's Prevention (WRAP). Analyses included descriptive indices of QDRS/CDR agreement, lasso logistic regression, tetrachoric correlations, and linear mixed models. RESULTS: The QDRS global/CDR global concordance rate is 70.66%. Memory item discrepancies were primarily responsible for QDRS/CDR global rating discordance. Average cognitive scores were highest in concordant‐normal QDRS/CDR and lowest in concordant‐abnormal QDRS/CDR. DISCUSSION: The QDRS effectively screened for impairment in this sample. Future analyses will investigate QDRS relations to ADRD biomarkers. Highlights: The Quick Dementia Rating System (QDRS) effectively screened for impairment in Alzheimer's disease and other dementias (ADRD) in a non‐demented sample. Concordance rate between QDRS CDR global and Clinical Dementia Rating (CDR) Scale global scores is 70.66%. Memory item discrepancies primarily cause QDRS/CDR global score discordance. Cognitive scores are associated with QDRS/CDR concordances/discordances. Future analyses will explore QDRS relations to ADRD biomarkers.
- 23 December 2024
- Published by Wiley in Alzheimer's & Dementia
- Vol. 21 (2)
Open AccessPerformance of study partner reports in a non‐demented at‐risk sample
INTRODUCTION: The Clinical Dementia Rating (CDR) Scale is a gold standard for staging impairment in Alzheimer's disease and other dementias (ADRD). The Quick Dementia Rating System (QDRS) offers similar results in 3 to 5 minutes without a trained clinician. This study aimed to (1) investigate concordance between comparably derived QDRS and CDR global scores, (2) examine item‐level QDRS/CDR agreement, and (3) compare sample characteristics and cognitive performance across QDRS/CDR global concordant/discordant groups. METHODS: The study included 351 QDRS/CDR pairs from 297 participants in the Wisconsin Registry for Alzheimer's Prevention (WRAP). Analyses included descriptive indices of QDRS/CDR agreement, lasso logistic regression, tetrachoric correlations, and linear mixed models. RESULTS: The QDRS global/CDR global concordance rate is 70.66%. Memory item discrepancies were primarily responsible for QDRS/CDR global rating discordance. Average cognitive scores were highest in concordant‐normal QDRS/CDR and lowest in concordant‐abnormal QDRS/CDR. DISCUSSION: The QDRS effectively screened for impairment in this sample. Future analyses will investigate QDRS relations to ADRD biomarkers. Highlights: The Quick Dementia Rating System (QDRS) effectively screened for impairment in Alzheimer's disease and other dementias (ADRD) in a non‐demented sample. Concordance rate between QDRS CDR global and Clinical Dementia Rating (CDR) Scale global scores is 70.66%. Memory item discrepancies primarily cause QDRS/CDR global score discordance. Cognitive scores are associated with QDRS/CDR concordances/discordances. Future analyses will explore QDRS relations to ADRD biomarkers.
- Open Access
- 27 March 2024
- Published by Wiley in Alzheimer's & Dementia
- Vol. 20 (5) , 3305-3321
Longitudinal normative standards for cognitive tests and composites using harmonized data from two Wisconsin AD‐risk‐enriched cohorts
INTRODUCTION: Published norms are typically cross‐sectional and often are not sensitive to preclinical cognitive changes due to dementia. We developed and validated demographically adjusted cross‐sectional and longitudinal normative standards using harmonized outcomes from two Alzheimer's disease (AD) risk‐enriched cohorts.METHODS: Data from the Wisconsin Registry for Alzheimer's Prevention and the Wisconsin Alzheimer's Disease Research Center were combined. Quantile regression was used to develop unconditional (cross‐sectional) and conditional (longitudinal) normative standards for 18 outcomes using data from cognitively unimpaired participants (N = 1390; mean follow‐up = 9.25 years). Validity analyses (N = 2456) examined relationships between percentile scores (centiles), consensus‐based cognitive statuses, and AD biomarker levels.RESULTS: Unconditional and conditional centiles were lower in those with consensus‐based impairment or biomarker positivity. Similarly, quantitative biomarker levels were higher in those whose centiles suggested decline.DISCUSSION: This study presents normative standards for cognitive measures sensitive to pre‐clinical changes. Future directions will investigate potential clinical applications of longitudinal normative standards.Highlights: Quantile regression was used to construct longitudinal norms for cognitive tests. Poorer percentile scores were related to concurrent diagnosis and Alzheimer's disease biomarkers. A ShinyApp was built to display test scores and norms and flag low performance.
- 27 March 2024
- Published by Wiley in Alzheimer's & Dementia
- Vol. 20 (5) , 3305-3321
Open AccessLongitudinal normative standards for cognitive tests and composites using harmonized data from two Wisconsin AD‐risk‐enriched cohorts
INTRODUCTION: Published norms are typically cross‐sectional and often are not sensitive to preclinical cognitive changes due to dementia. We developed and validated demographically adjusted cross‐sectional and longitudinal normative standards using harmonized outcomes from two Alzheimer's disease (AD) risk‐enriched cohorts.METHODS: Data from the Wisconsin Registry for Alzheimer's Prevention and the Wisconsin Alzheimer's Disease Research Center were combined. Quantile regression was used to develop unconditional (cross‐sectional) and conditional (longitudinal) normative standards for 18 outcomes using data from cognitively unimpaired participants (N = 1390; mean follow‐up = 9.25 years). Validity analyses (N = 2456) examined relationships between percentile scores (centiles), consensus‐based cognitive statuses, and AD biomarker levels.RESULTS: Unconditional and conditional centiles were lower in those with consensus‐based impairment or biomarker positivity. Similarly, quantitative biomarker levels were higher in those whose centiles suggested decline.DISCUSSION: This study presents normative standards for cognitive measures sensitive to pre‐clinical changes. Future directions will investigate potential clinical applications of longitudinal normative standards.Highlights: Quantile regression was used to construct longitudinal norms for cognitive tests. Poorer percentile scores were related to concurrent diagnosis and Alzheimer's disease biomarkers. A ShinyApp was built to display test scores and norms and flag low performance.
- Open Access
- 16 November 2023
- Published by MDPI AG in Metabolites
- Vol. 13 (11) , 1154
Assessing the Biological Mechanisms Linking Smoking Behavior and Cognitive Function: A Mediation Analysis of Untargeted Metabolomics
(1) Smoking is the most significant preventable health hazard in the modern world. It increases the risk of vascular problems, which are also risk factors for dementia. In addition, toxins in cigarettes increase oxidative stress and inflammation, which have both been linked to the development of Alzheimer’s disease and related dementias (ADRD). This study identified potential mechanisms of the smoking–cognitive function relationship using metabolomics data from the longitudinal Wisconsin Registry for Alzheimer’s Prevention (WRAP). (2) 1266 WRAP participants were included to assess the association between smoking status and four cognitive composite scores. Next, untargeted metabolomic data were used to assess the relationships between smoking and metabolites. Metabolites significantly associated with smoking were then tested for association with cognitive composite scores. Total effect models and mediation models were used to explore the role of metabolites in smoking-cognitive function pathways. (3) Plasma N-acetylneuraminate was associated with smoking status Preclinical Alzheimer Cognitive Composite 3 (PACC3) and Immediate Learning (IMM). N-acetylneuraminate mediated 12% of the smoking-PACC3 relationship and 13% of the smoking-IMM relationship. (4) These findings provide links between previous studies that can enhance our understanding of potential biological pathways between smoking and cognitive function.
- 16 November 2023
- Published by MDPI AG in Metabolites
- Vol. 13 (11) , 1154
Open AccessAssessing the Biological Mechanisms Linking Smoking Behavior and Cognitive Function: A Mediation Analysis of Untargeted Metabolomics
(1) Smoking is the most significant preventable health hazard in the modern world. It increases the risk of vascular problems, which are also risk factors for dementia. In addition, toxins in cigarettes increase oxidative stress and inflammation, which have both been linked to the development of Alzheimer’s disease and related dementias (ADRD). This study identified potential mechanisms of the smoking–cognitive function relationship using metabolomics data from the longitudinal Wisconsin Registry for Alzheimer’s Prevention (WRAP). (2) 1266 WRAP participants were included to assess the association between smoking status and four cognitive composite scores. Next, untargeted metabolomic data were used to assess the relationships between smoking and metabolites. Metabolites significantly associated with smoking were then tested for association with cognitive composite scores. Total effect models and mediation models were used to explore the role of metabolites in smoking-cognitive function pathways. (3) Plasma N-acetylneuraminate was associated with smoking status Preclinical Alzheimer Cognitive Composite 3 (PACC3) and Immediate Learning (IMM). N-acetylneuraminate mediated 12% of the smoking-PACC3 relationship and 13% of the smoking-IMM relationship. (4) These findings provide links between previous studies that can enhance our understanding of potential biological pathways between smoking and cognitive function.
- Open Access
- 1 November 2023
- Published by Oxford University Press (OUP) in Brain Communications
- Vol. 5 (6) , fcad333
Harnessing cognitive trajectory clusterings to examine subclinical decline risk factors
Cognitive decline in Alzheimer’s disease and other dementias typically begins long before clinical impairment. Identifying people experiencing subclinical decline may facilitate earlier intervention. This study developed cognitive trajectory clusters using longitudinally based random slope and change point parameter estimates from a Preclinical Alzheimer’s disease Cognitive Composite and examined how baseline and most recently available clinical/health-related characteristics, cognitive statuses and biomarkers for Alzheimer’s disease and vascular disease varied across these cognitive clusters. Data were drawn from the Wisconsin Registry for Alzheimer’s Prevention, a longitudinal cohort study of adults from late midlife, enriched for a parental history of Alzheimer’s disease and without dementia at baseline. Participants who were cognitively unimpaired at the baseline visit with ≥3 cognitive visits were included in trajectory modelling (n = 1068). The following biomarker data were available for subsets: positron emission tomography amyloid (amyloid: n = 367; [11C]Pittsburgh compound B (PiB): global PiB distribution volume ratio); positron emission tomography tau (tau: n = 321; [18F]MK-6240: primary regions of interest meta-temporal composite); MRI neurodegeneration (neurodegeneration: n = 581; hippocampal volume and global brain atrophy); T2 fluid-attenuated inversion recovery MRI white matter ischaemic lesion volumes (vascular: white matter hyperintensities; n = 419); and plasma pTau217 (n = 165). Posterior median estimate person-level change points, slopes’ pre- and post-change point and estimated outcome (intercepts) at change point for cognitive composite were extracted from Bayesian Bent-Line Regression modelling and used to characterize cognitive trajectory groups (K-means clustering). A common method was used to identify amyloid/tau/neurodegeneration/vascular biomarker thresholds. We compared demographics, last visit cognitive status, health-related factors and amyloid/tau/neurodegeneration/vascular biomarkers across the cognitive groups using ANOVA, Kruskal–Wallis, χ2, and Fisher’s exact tests. Mean (standard deviation) baseline and last cognitive assessment ages were 58.4 (6.4) and 66.6 (6.6) years, respectively. Cluster analysis identified three cognitive trajectory groups representing steep, n = 77 (7.2%); intermediate, n = 446 (41.8%); and minimal, n = 545 (51.0%) cognitive decline. The steep decline group was older, had more females, APOE e4 carriers and mild cognitive impairment/dementia at last visit; it also showed worse self-reported general health-related and vascular risk factors and higher amyloid, tau, neurodegeneration and white matter hyperintensity positive proportions at last visit. Subtle cognitive decline was consistently evident in the steep decline group and was associated with generally worse health. In addition, cognitive trajectory groups differed on aetiology-informative biomarkers and risk factors, suggesting an intimate link between preclinical cognitive patterns and amyloid/tau/neurodegeneration/vascular biomarker differences in late middle-aged adults. The result explains some of the heterogeneity in cognitive performance within cognitively unimpaired late middle-aged adults.
- 1 November 2023
- Published by Oxford University Press (OUP) in Brain Communications
- Vol. 5 (6) , fcad333
Open AccessHarnessing cognitive trajectory clusterings to examine subclinical decline risk factors
Cognitive decline in Alzheimer’s disease and other dementias typically begins long before clinical impairment. Identifying people experiencing subclinical decline may facilitate earlier intervention. This study developed cognitive trajectory clusters using longitudinally based random slope and change point parameter estimates from a Preclinical Alzheimer’s disease Cognitive Composite and examined how baseline and most recently available clinical/health-related characteristics, cognitive statuses and biomarkers for Alzheimer’s disease and vascular disease varied across these cognitive clusters. Data were drawn from the Wisconsin Registry for Alzheimer’s Prevention, a longitudinal cohort study of adults from late midlife, enriched for a parental history of Alzheimer’s disease and without dementia at baseline. Participants who were cognitively unimpaired at the baseline visit with ≥3 cognitive visits were included in trajectory modelling (n = 1068). The following biomarker data were available for subsets: positron emission tomography amyloid (amyloid: n = 367; [11C]Pittsburgh compound B (PiB): global PiB distribution volume ratio); positron emission tomography tau (tau: n = 321; [18F]MK-6240: primary regions of interest meta-temporal composite); MRI neurodegeneration (neurodegeneration: n = 581; hippocampal volume and global brain atrophy); T2 fluid-attenuated inversion recovery MRI white matter ischaemic lesion volumes (vascular: white matter hyperintensities; n = 419); and plasma pTau217 (n = 165). Posterior median estimate person-level change points, slopes’ pre- and post-change point and estimated outcome (intercepts) at change point for cognitive composite were extracted from Bayesian Bent-Line Regression modelling and used to characterize cognitive trajectory groups (K-means clustering). A common method was used to identify amyloid/tau/neurodegeneration/vascular biomarker thresholds. We compared demographics, last visit cognitive status, health-related factors and amyloid/tau/neurodegeneration/vascular biomarkers across the cognitive groups using ANOVA, Kruskal–Wallis, χ2, and Fisher’s exact tests. Mean (standard deviation) baseline and last cognitive assessment ages were 58.4 (6.4) and 66.6 (6.6) years, respectively. Cluster analysis identified three cognitive trajectory groups representing steep, n = 77 (7.2%); intermediate, n = 446 (41.8%); and minimal, n = 545 (51.0%) cognitive decline. The steep decline group was older, had more females, APOE e4 carriers and mild cognitive impairment/dementia at last visit; it also showed worse self-reported general health-related and vascular risk factors and higher amyloid, tau, neurodegeneration and white matter hyperintensity positive proportions at last visit. Subtle cognitive decline was consistently evident in the steep decline group and was associated with generally worse health. In addition, cognitive trajectory groups differed on aetiology-informative biomarkers and risk factors, suggesting an intimate link between preclinical cognitive patterns and amyloid/tau/neurodegeneration/vascular biomarker differences in late middle-aged adults. The result explains some of the heterogeneity in cognitive performance within cognitively unimpaired late middle-aged adults.
- Open Access
- 30 October 2023
- Published by MDPI AG in Brain Sciences
- Vol. 13 (11) , 1530
Comparison of the 10-, 14- and 20-Item CES-D Scores as Predictors of Cognitive Decline
The association between depressive symptomatology and cognitive decline has been examined using the Centre for Epidemiologic Studies-Depression Scale (CES-D); however, concerns have been raised about this self-report measure. Here, we examined how the CES-D total score from the 14- and 10-item versions compared to the 20-item version in predicting progression to cognitive decline from a cognitively unimpaired baseline. Data from 1054 participants were analysed using ordinal logistic regression, alongside moderator and receiver-operating characteristics curve analyses. All baseline total scores significantly predicted progression to cognitive decline. The 14-item version was better than the 20-item version in predicting consensus diagnosis, as shown by their AICs, while also showing the highest accuracy when discriminating between participants by diagnosis at last visit. We did not find sex to moderate the relationship between CES-D score and cognitive decline. Current findings suggest the 10- and 14-item versions of the CES-D are comparable to the 20-item version, and that the 14-item version may be better at predicting longitudinal consensus diagnosis compared to the 20-item version.
- 30 October 2023
- Published by MDPI AG in Brain Sciences
- Vol. 13 (11) , 1530
Open AccessComparison of the 10-, 14- and 20-Item CES-D Scores as Predictors of Cognitive Decline
The association between depressive symptomatology and cognitive decline has been examined using the Centre for Epidemiologic Studies-Depression Scale (CES-D); however, concerns have been raised about this self-report measure. Here, we examined how the CES-D total score from the 14- and 10-item versions compared to the 20-item version in predicting progression to cognitive decline from a cognitively unimpaired baseline. Data from 1054 participants were analysed using ordinal logistic regression, alongside moderator and receiver-operating characteristics curve analyses. All baseline total scores significantly predicted progression to cognitive decline. The 14-item version was better than the 20-item version in predicting consensus diagnosis, as shown by their AICs, while also showing the highest accuracy when discriminating between participants by diagnosis at last visit. We did not find sex to moderate the relationship between CES-D score and cognitive decline. Current findings suggest the 10- and 14-item versions of the CES-D are comparable to the 20-item version, and that the 14-item version may be better at predicting longitudinal consensus diagnosis compared to the 20-item version.
- Open Access
- 21 September 2023
- Published by MDPI AG in Preprints.org
Comparison of the 10-, 14- and 20-Item CES-D Scores as Predictors of Cognitive Decline
The association between depressive symptomatology and cognitive decline has been examined using the Centre for Epidemiologic Studies-Depression Scale (CES-D), however, concerns have been raised about this self-report measure. Here, we examined how the CES-D total score from the 14- and 10-item versions compared to the 20-item version in predicting progression to cognitive decline from a cognitively unimpaired baseline. Data from 1,054 participants were analysed using ordinal logistic regression, alongside moderator and receiver-operating characteristics curve analyses. All baseline total scores significantly predicted progression to cognitive decline. The 14-item version was better than the 20-item version in predicting consensus diagnosis, as shown by their AICs, while also showing the highest accuracy when discriminating between participants by diagnosis at last visit. We did not find sex to moderate the relationship between CES-D score and cognitive decline. Current findings suggest the 10- and 14-item versions of the CES-D are comparable to the 20-item version, and that the 14-item version may be better at predicting longitudinal consensus diagnosis compared to the 20-item version.
- 21 September 2023
- Published by MDPI AG in Preprints.org
Open AccessComparison of the 10-, 14- and 20-Item CES-D Scores as Predictors of Cognitive Decline
The association between depressive symptomatology and cognitive decline has been examined using the Centre for Epidemiologic Studies-Depression Scale (CES-D), however, concerns have been raised about this self-report measure. Here, we examined how the CES-D total score from the 14- and 10-item versions compared to the 20-item version in predicting progression to cognitive decline from a cognitively unimpaired baseline. Data from 1,054 participants were analysed using ordinal logistic regression, alongside moderator and receiver-operating characteristics curve analyses. All baseline total scores significantly predicted progression to cognitive decline. The 14-item version was better than the 20-item version in predicting consensus diagnosis, as shown by their AICs, while also showing the highest accuracy when discriminating between participants by diagnosis at last visit. We did not find sex to moderate the relationship between CES-D score and cognitive decline. Current findings suggest the 10- and 14-item versions of the CES-D are comparable to the 20-item version, and that the 14-item version may be better at predicting longitudinal consensus diagnosis compared to the 20-item version.